Article
Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay.
Oncotarget - 1 Mar 2016
Schwaederle Maria, Husain Hatim, Fanta Paul T, Piccioni David E, Kesari Santosh, Schwab Richard B, Banks Kimberly C, Lanman Richard B, Talasaz AmirAli, Parker Barbara A, Kurzrock Razelle
Abstract excerpt
Analysis of cell-free DNA using next-generation sequencing (NGS) is a powerful tool for the detection/monitoring of alterations present in circulating tumor DNA (ctDNA). Plasma extracted from 171 patients with a variety of cancers was analyzed for ctDNA (54 genes and copy number variants (CNVs) in three genes (EGFR, ERBB2 and MET)). The most represented cancers were lung (23%), breast (23%), and glioblastoma...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.